Navigation Links
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
Date:1/24/2008

- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy

in Gastroesophageal and Colorectal Cancers -

NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in Orlando, Fla., from Jan. 25 to 27.

Five poster presentations based on U.S. data offer additional knowledge about Xeloda. Two of these U.S. abstracts compare the safety profile and usage patterns of therapy with oral Xeloda to that of intravenous fluorouracil (5-FU) therapy in gastroesophageal cancer. A second pair of U.S. abstracts evaluates the usage patterns and cost of Xeloda-based regimens against those of 5-FU-based regimens in colon and rectal cancer. The fifth U.S. abstract highlights preclinical efficacy and tolerability results of a novel Xeloda regimen (7/7, or 7 days on, 7 days off) using higher daily doses for the treatment of colorectal cancer.
-- Jan. 25, noon to 1 p.m., [Poster No. 72], A claims database analysis of

capecitabine treatment patterns in patients with gastroesophageal

cancer (GEC) (Presenter: Wasif Saif)

-- Jan. 25, noon to 1 p.m., [Poster No. 71], Capecitabine in patients with

gastroesophageal cancer (GEC): A claims database analysis of adverse

events (AEs) (Presenter: Wasif Saif)

-- Jan. 26, 5:30 to 6:30 p.m., [Poster No. 364], A claims database cost-

comparison analysis of capecitabine in the treatment of patients with

colon or rectal cancer (CRC) (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. 465], Capecitabine use in patients

with colon and rectal cancer (CRC): A claims database analysis of

treatment (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. A29], In vivo activity of traditional

vs. novel regimens of capecitabine (C) alone and in combination in a

colorectal cancer xenograft model (Presenter: Kenneth Kolinsky)

Collectively, the findings of these studies highlight the efficacy and safety of oral Xeloda as a potential alternative to 5-FU in gastroesophageal and colorectal cancers and support further clinical testing to examine the efficacy and safety benefits of the 7/7 Xeloda dosing regimen. Global data presentations, including a meta-analysis that compares the overall survival benefit between Xeloda and 5-FU in adjuvant and metastatic settings, provide similar insights.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune). For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or http://www.roche.us.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
6. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
7. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
8. Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
9. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/4/2016)... ... ... Dr. Elyson and Dr. Assili, dentist in Northridge , announce that they ... common dental procedure, is performed for many adolescents and young adults today. While wisdom ... complications. By providing wisdom tooth removal surgery at their office, Dr. Elyson and Dr. ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental business ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and driving ... her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in both ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There ... UTIs, have plagued people since the beginning of recorded medical history, and in ... every year. It's not just a matter of inconvenience; bladder infections cost us billions ...
Breaking Medicine News(10 mins):